Maples and Calder Advises Biohaven Pharmaceutical on US$195m IPO
Maples and Calder has advised Biohaven Pharmaceutical Holding Company Ltd ("Biohaven") on its initial public offering ("IPO") on the New York Stock Exchange, which closed in May 2017 at approximately US$195 million.
The Maples and Calder team was led by BVI-based partners Richard May and Chris Newton with the assistance of associate Daniel Perkins.
"Transactions such as these highlight the flexibility of the BVI as a jurisdiction and the suitability of BVI entities for a wide range of uses, including IPOs," said Maples and Calder's BVI Managing Partner, Richard May. "We are pleased to have assisted Biohaven on this significant achievement and look forward to continuing to work with them as the business progresses."
A long standing client of the firm, Maples and Calder has acted as Biohaven's legal adviser since its incorporation and continues to advise the company on its corporate matters.